Compare ACH & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ACH | ELOX |
|---|---|---|
| Founded | 1882 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.4M | 60.3M |
| IPO Year | 2001 | 2013 |
| Metric | ACH | ELOX |
|---|---|---|
| Price | $0.43 | $14.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $1.51 | ★ $38.25 |
| AVG Volume (30 Days) | ★ 1.3M | 18.6K |
| Earning Date | 10-29-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,762,032,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.44 | $10.00 |
| 52 Week High | $4.69 | $23.40 |
| Indicator | ACH | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 16.16 | 43.09 |
| Support Level | N/A | $13.98 |
| Resistance Level | $1.26 | $19.43 |
| Average True Range (ATR) | 0.06 | 1.26 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 0.02 | 20.31 |
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.